vs
Solo Brands, Inc.（SBDS）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是Solo Brands, Inc.的1.4倍（$127.1M vs $94.0M），再鼎医药同比增速更快（17.1% vs -34.5%），过去两年再鼎医药的营收复合增速更高（20.8% vs 5.0%）
给定公司标识与企业信息不匹配，本次提供的实为康尼格拉品牌公司信息，该企业是美国上市消费品包装集团，产品在超市、餐饮门店均有售，总部坐落于美国伊利诺伊州芝加哥，1919年创始于美国内布拉斯加州，按2021年营收位列2022年财富世界500强第331位。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
SBDS vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.4倍
$94.0M
营收增速更快
ZLAB
高出51.6%
-34.5%
两年增速更快
ZLAB
近两年复合增速
5.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.0M | $127.1M |
| 净利润 | $-83.2M | — |
| 毛利率 | 60.6% | 51.0% |
| 营业利润率 | -81.7% | -54.6% |
| 净利率 | -88.4% | — |
| 营收同比 | -34.5% | 17.1% |
| 净利润同比 | -42.9% | — |
| 每股收益（稀释后） | $-45.73 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SBDSZLAB
| Q4 25 | $94.0M | $127.1M | ||
| Q3 25 | $53.0M | $115.4M | ||
| Q2 25 | $92.3M | $109.1M | ||
| Q1 25 | $77.3M | $105.7M | ||
| Q4 24 | $143.5M | $108.5M | ||
| Q3 24 | $94.1M | $101.8M | ||
| Q2 24 | $131.6M | $100.1M | ||
| Q1 24 | $85.3M | $87.1M |
净利润SBDSZLAB
| Q4 25 | $-83.2M | — | ||
| Q3 25 | $-22.9M | $-36.0M | ||
| Q2 25 | $-20.8M | $-40.7M | ||
| Q1 25 | $-18.6M | $-48.4M | ||
| Q4 24 | $-58.2M | — | ||
| Q3 24 | $-111.5M | $-41.7M | ||
| Q2 24 | $-4.0M | $-80.3M | ||
| Q1 24 | $-6.5M | $-53.5M |
毛利率SBDSZLAB
| Q4 25 | 60.6% | 51.0% | ||
| Q3 25 | 60.0% | 59.5% | ||
| Q2 25 | 61.3% | 60.6% | ||
| Q1 25 | 55.2% | 63.6% | ||
| Q4 24 | 61.1% | 61.5% | ||
| Q3 24 | 41.8% | 64.1% | ||
| Q2 24 | 62.8% | 64.9% | ||
| Q1 24 | 59.2% | 61.4% |
营业利润率SBDSZLAB
| Q4 25 | -81.7% | -54.6% | ||
| Q3 25 | -30.5% | -42.3% | ||
| Q2 25 | -10.7% | -50.3% | ||
| Q1 25 | -13.8% | -53.3% | ||
| Q4 24 | -38.5% | -62.6% | ||
| Q3 24 | -122.5% | -66.6% | ||
| Q2 24 | 1.7% | -76.0% | ||
| Q1 24 | -7.4% | -80.7% |
净利率SBDSZLAB
| Q4 25 | -88.4% | — | ||
| Q3 25 | -43.2% | -31.2% | ||
| Q2 25 | -22.5% | -37.3% | ||
| Q1 25 | -24.0% | -45.8% | ||
| Q4 24 | -40.6% | — | ||
| Q3 24 | -118.4% | -40.9% | ||
| Q2 24 | -3.1% | -80.2% | ||
| Q1 24 | -7.6% | -61.4% |
每股收益（稀释后）SBDSZLAB
| Q4 25 | $-45.73 | $-0.05 | ||
| Q3 25 | $-9.22 | $-0.03 | ||
| Q2 25 | $-8.93 | $-0.04 | ||
| Q1 25 | $-0.21 | $-0.04 | ||
| Q4 24 | $-27.74 | $-0.09 | ||
| Q3 24 | $-47.72 | $-0.04 | ||
| Q2 24 | $-2.14 | $-0.08 | ||
| Q1 24 | $-0.06 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.0M | $689.6M |
| 总债务越低越好 | $242.1M | — |
| 股东权益账面价值 | $46.0M | $715.5M |
| 总资产 | $360.3M | $1.2B |
| 负债/权益比越低杠杆越低 | 5.26× | — |
8季度趋势，按日历期对齐
现金及短期投资SBDSZLAB
| Q4 25 | $20.0M | $689.6M | ||
| Q3 25 | $16.3M | $717.2M | ||
| Q2 25 | $18.1M | $732.2M | ||
| Q1 25 | $206.4M | $757.3M | ||
| Q4 24 | $12.0M | $779.7M | ||
| Q3 24 | $12.5M | $616.1M | ||
| Q2 24 | $20.1M | $630.0M | ||
| Q1 24 | $15.4M | $650.8M |
总债务SBDSZLAB
| Q4 25 | $242.1M | — | ||
| Q3 25 | $235.2M | — | ||
| Q2 25 | $238.4M | — | ||
| Q1 25 | $427.9M | — | ||
| Q4 24 | $150.7M | — | ||
| Q3 24 | $161.1M | — | ||
| Q2 24 | $162.2M | — | ||
| Q1 24 | $170.2M | — |
股东权益SBDSZLAB
| Q4 25 | $46.0M | $715.5M | ||
| Q3 25 | $99.1M | $759.9M | ||
| Q2 25 | $113.2M | $791.7M | ||
| Q1 25 | $121.7M | $810.8M | ||
| Q4 24 | $133.7M | $840.9M | ||
| Q3 24 | $168.0M | $667.7M | ||
| Q2 24 | $236.7M | $704.2M | ||
| Q1 24 | $238.5M | $762.2M |
总资产SBDSZLAB
| Q4 25 | $360.3M | $1.2B | ||
| Q3 25 | $431.0M | $1.2B | ||
| Q2 25 | $459.7M | $1.2B | ||
| Q1 25 | $692.4M | $1.2B | ||
| Q4 24 | $495.1M | $1.2B | ||
| Q3 24 | $553.2M | $985.3M | ||
| Q2 24 | $642.0M | $987.4M | ||
| Q1 24 | $648.3M | $988.4M |
负债/权益比SBDSZLAB
| Q4 25 | 5.26× | — | ||
| Q3 25 | 2.37× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 3.52× | — | ||
| Q4 24 | 1.13× | — | ||
| Q3 24 | 0.96× | — | ||
| Q2 24 | 0.69× | — | ||
| Q1 24 | 0.71× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.4M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | — | $-26.7M |
| 自由现金流率自由现金流/营收 | — | -21.0% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-158.9M |
8季度趋势，按日历期对齐
经营现金流SBDSZLAB
| Q4 25 | $6.4M | $-26.0M | ||
| Q3 25 | $11.2M | $-32.0M | ||
| Q2 25 | $10.9M | $-31.0M | ||
| Q1 25 | $-75.2M | $-61.7M | ||
| Q4 24 | $13.0M | $-55.8M | ||
| Q3 24 | $378.0K | $-26.8M | ||
| Q2 24 | $15.7M | $-42.2M | ||
| Q1 24 | $-18.5M | $-90.1M |
自由现金流SBDSZLAB
| Q4 25 | — | $-26.7M | ||
| Q3 25 | — | $-35.0M | ||
| Q2 25 | — | $-33.9M | ||
| Q1 25 | $-78.4M | $-63.2M | ||
| Q4 24 | $9.0M | $-58.4M | ||
| Q3 24 | $-5.9M | $-28.2M | ||
| Q2 24 | $12.8M | $-42.9M | ||
| Q1 24 | $-20.9M | $-91.1M |
自由现金流率SBDSZLAB
| Q4 25 | — | -21.0% | ||
| Q3 25 | — | -30.4% | ||
| Q2 25 | — | -31.1% | ||
| Q1 25 | -101.5% | -59.9% | ||
| Q4 24 | 6.3% | -53.8% | ||
| Q3 24 | -6.3% | -27.7% | ||
| Q2 24 | 9.8% | -42.9% | ||
| Q1 24 | -24.5% | -104.5% |
资本支出强度SBDSZLAB
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | 4.2% | 1.5% | ||
| Q4 24 | 2.8% | 2.4% | ||
| Q3 24 | 6.7% | 1.3% | ||
| Q2 24 | 2.2% | 0.7% | ||
| Q1 24 | 2.8% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SBDS
| Sales Channel Directly To Consumer | $65.4M | 70% |
| Sales Channel Through Intermediary | $28.6M | 30% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
